Company Overview of Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical tr...
88 Sidney Street
Cambridge, MA 02139
Founded in 2007
Key Executives for Agios Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $517.5K
Chief Medical Officer
Total Annual Compensation: $553.8K
Chief Scientific Officer
Total Annual Compensation: $400.9K
Compensation as of Fiscal Year 2015.
Agios Pharmaceuticals, Inc. Key Developments
Agios Pharmaceuticals, Inc. Appoints Ian Clark to Board of Directors
Jan 3 17
Agios Pharmaceuticals, Inc. announced the appointment of Ian Clark to its board of directors. Most recently, Mr. Clark served as the chief executive officer and member of the board of directors at Genentech. Prior to his role of chief executive officer, Mr. Clark held executive management roles at Genentech, including head of global product strategy, chief marketing officer, senior vice president, general manager of biooncology and executive vice president for commercial operations. Prior to these roles, Mr. Clark served as general manager, Novartis Canada and chief operating officer for Novartis U.K. Before joining Novartis, Mr. Clark served in positions of increasing strategic importance in sales, marketing and business development at Ivax Pharma and Sanofi in the United Kingdom, France and Eastern Europe. Concurrent with the appointment of Mr. Clark, Douglas G. Cole, M.D., managing partner at Flagship Pioneering, has resigned from the company’s board of directors and the nominating and corporate governance committee of the board of directors, effective January 2, 2017.
Agios Pharmaceuticals, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 10:00 AM
Jan 3 17
Agios Pharmaceuticals, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: David P. Schenkein, Chief Executive Officer, President and Director.
Agios Pharmaceuticals, Inc Provides Update on PKR Program
Dec 15 16
Agios Pharmaceuticals, Inc. announced that it is no longer developing its second pyruvate kinase-R activator, AG-519, and withdrew its investigational new drug application on December 14, 2016 following a verbal notification of a clinical hold from the U.S. Food and Drug Administration. These decisions do not affect the company’s ongoing global Phase 2 study for AG-348, a novel, first-in-class activator of both wild-type (normal) and mutated PKR enzymes. Agios is advancing AG-348 into pivotal development as the first potential disease-modifying treatment for pyruvate kinase deficiency. DRIVE PK is an ongoing global Phase 2, open-label safety and efficacy trial and the first study evaluating AG-348 in adult, transfusion-independent patients with PK deficiency. The study target enrollment has been reached with a total of 52 patients. In total, 124 patients and healthy volunteers have been treated with AG-348 since studies were initiated in 2014. As of the September 23, 2016 data cut-off, AG-348 was well-tolerated with the majority of treatment-related adverse events Grade 1-2; the most frequent being headache, nausea and insomnia. AG-348 also demonstrated clinically relevant, rapid and sustained hemoglobin increases in 15 of 26 patients with at least one missense mutation, and in 15 out of 32 patients overall. AG-519 was evaluated in a Phase 1 healthy volunteer study in the United Kingdom to assess safety, tolerability, pharmacokinetics, pharmacodynamics and bioavailability. A previously disclosed case of drug-induced cholestatic hepatitis occurred in the bioavailability portion of the study and this volunteer continues to be monitored. No additional adverse events have been reported. In addition, AG-519 was undergoing a palatability study in volunteers in the United States to develop a formulation for potential future development. In total, 98 volunteers have received AG-519 and no volunteers or patients are currently receiving the drug.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|